Suppr超能文献

美国抗痴呆药物的治疗模式:医疗保险队列研究

Treatment Patterns with Antidementia Drugs in the United States: Medicare Cohort Study.

作者信息

Koller Daniela, Hua Tammy, Bynum Julie P W

机构信息

Department of Health Services Management, Munich School of Management, Ludwig Maximilian University of Munich, Munich, Germany.

Dartmouth College, Hanover, New Hampshire.

出版信息

J Am Geriatr Soc. 2016 Aug;64(8):1540-8. doi: 10.1111/jgs.14226. Epub 2016 Jun 24.

Abstract

OBJECTIVES

To evaluate frequency of use of two anti-dementia drug classes approved for treatment of symptoms, whether populations most likely to benefit are treated, and correlates of treatment initiation.

DESIGN

Nationally representative cohort study.

SETTING

Fee-for-service Medicare.

PARTICIPANTS

Elderly adults with dementia enrolled in Medicare Parts A, B, and D in 2009 (N = 433,559) and a subset with incident dementia (n = 185,449).

MEASUREMENTS

Main outcome was any prescription fill for antidementia drugs (cholinesterase inhibitors (ChEIs) or memantine) within 1 year.

RESULTS

Treatment with antidementia drugs occurred in 55.8% of all participants with dementia and 49.3% of those with incident dementia. There was no difference between ChEIs and memantine use according to dementia severity (measured as death within first year or living in residential care vs in a community setting) even though memantine is not indicated in mild disease. In incident cases, initiation of treatment was lower in residential care (relative risk (RR) = 0.82, 95% confidence interval (CI) = 0.81-0.83) and with more comorbidities (RR = 0.96, 95% CI = 0.96-0.96). Sixty percent of participants were managed in primary care alone. Seeing a neurologist (RR = 1.07, 95% CI = 1.06-1.09) or psychiatrist (RR = 1.17, 95% CI = 1.16-1.19) was associated with higher likelihood of treatment than seeing a primary care provider alone, and seeing geriatrician was associated with with lower likelihood (RR = 0.96, 95% CI = 0.93-0.99). Across the United States, the proportion of newly diagnosed individuals started on antidementia treatment varied from 32% to 66% across hospital referral regions.

CONCLUSION

Antidementia drugs are used less often in people with late disease, but there is no differentiation in medication choice. Although primary care providers most often prescribe antidementia medication without specialty support, differences in practice between specialties are evident.

摘要

目的

评估两类已获批用于治疗症状的抗痴呆药物的使用频率、最可能受益的人群是否得到治疗以及治疗起始的相关因素。

设计

具有全国代表性的队列研究。

背景

按服务收费的医疗保险。

参与者

2009年参加医疗保险A、B和D部分的老年痴呆症患者(N = 433,559)以及一部分新发痴呆症患者(n = 185,449)。

测量指标

主要结局是在1年内是否有任何抗痴呆药物(胆碱酯酶抑制剂(ChEIs)或美金刚)的处方配药。

结果

所有痴呆症患者中有55.8%接受了抗痴呆药物治疗,新发痴呆症患者中有49.3%接受了治疗。尽管美金刚未被批准用于轻度疾病,但根据痴呆症严重程度(以第一年死亡或居住在机构护理与社区环境来衡量),ChEIs和美金刚的使用情况并无差异。在新发病例中,机构护理患者的治疗起始率较低(相对风险(RR)= 0.82,95%置信区间(CI)= 0.81 - 0.83),且合并症较多的患者治疗起始率也较低(RR = 0.96,95% CI = 0.96 - 0.96)。60%的参与者仅由初级保健医生管理。与仅看初级保健医生相比,看神经科医生(RR = 1.07,95% CI = 1.06 - 1.09)或精神科医生(RR = 1.17,95% CI = 1.16 - 1.19)的患者接受治疗的可能性更高,而看老年病医生的患者接受治疗的可能性较低(RR = 0.96,95% CI = 0.93 - 0.99)。在美国各地,新诊断个体开始接受抗痴呆治疗的比例在不同医院转诊区域从32%到66%不等。

结论

晚期疾病患者使用抗痴呆药物的频率较低,但在药物选择上没有差异。尽管初级保健医生最常在没有专科支持的情况下开具抗痴呆药物,但各专科之间的实践差异明显。

相似文献

1
Treatment Patterns with Antidementia Drugs in the United States: Medicare Cohort Study.
J Am Geriatr Soc. 2016 Aug;64(8):1540-8. doi: 10.1111/jgs.14226. Epub 2016 Jun 24.
2
Effect of Medicare Part D on Ethnoracial Disparities in Antidementia Medication Use.
J Am Geriatr Soc. 2018 Sep;66(9):1760-1767. doi: 10.1111/jgs.15494. Epub 2018 Aug 10.
3
Racial and Ethnic Differences in Initiation and Discontinuation of Antidementia Drugs by Medicare Beneficiaries.
J Am Geriatr Soc. 2016 Sep;64(9):1806-14. doi: 10.1111/jgs.14403. Epub 2016 Aug 22.
4
The impact of Medicare prescription drug coverage on the use of antidementia drugs.
BMC Geriatr. 2013 Apr 27;13:37. doi: 10.1186/1471-2318-13-37.
8
Continuous treatment with antidementia drugs in Germany 2003-2013: a retrospective database analysis.
Int Psychogeriatr. 2015 Aug;27(8):1335-42. doi: 10.1017/S1041610215000654. Epub 2015 Apr 22.
9
Comparative cardiovascular safety of dementia medications: a cross-national study.
J Am Geriatr Soc. 2012 Dec;60(12):2283-9. doi: 10.1111/j.1532-5415.2012.04241.x. Epub 2012 Nov 23.

引用本文的文献

1
The National Dementia Workforce Study: Overview.
J Am Geriatr Soc. 2025 Sep 1. doi: 10.1111/jgs.70061.
3
Patterns and predictors of cholinesterase inhibitor use in dementia with Lewy bodies.
Alzheimers Dement (N Y). 2025 Jul 19;11(3):e70136. doi: 10.1002/trc2.70136. eCollection 2025 Jul-Sep.
7
Non-adherence to antidementia medications and associated factors: a study of Spanish population-based registry data.
Front Pharmacol. 2024 Nov 5;15:1425442. doi: 10.3389/fphar.2024.1425442. eCollection 2024.
8
Geographic Variation of Antidementia and Antipsychotic Medication Use Among US Nursing Home Residents With Dementia.
Med Care. 2024 Aug 1;62(8):511-520. doi: 10.1097/MLR.0000000000002016. Epub 2024 May 29.
10
Antidementia Medication Use in Nursing Home Residents.
J Geriatr Psychiatry Neurol. 2024 May;37(3):194-205. doi: 10.1177/08919887231202948. Epub 2023 Sep 16.

本文引用的文献

1
Dementia in the USA: state variation in prevalence.
J Public Health (Oxf). 2015 Dec;37(4):597-604. doi: 10.1093/pubmed/fdu080. Epub 2014 Oct 20.
3
Use of medications of questionable benefit in advanced dementia.
JAMA Intern Med. 2014 Nov;174(11):1763-71. doi: 10.1001/jamainternmed.2014.4103.
5
Galantamine for vascular cognitive impairment.
Cochrane Database Syst Rev. 2006 Jan 25(4):CD004746. doi: 10.1002/14651858.CD004746.pub2.
6
The impact of Medicare prescription drug coverage on the use of antidementia drugs.
BMC Geriatr. 2013 Apr 27;13:37. doi: 10.1186/1471-2318-13-37.
7
Monetary costs of dementia in the United States.
N Engl J Med. 2013 Apr 4;368(14):1326-34. doi: 10.1056/NEJMsa1204629.
8
Alzheimer disease in the United States (2010-2050) estimated using the 2010 census.
Neurology. 2013 May 7;80(19):1778-83. doi: 10.1212/WNL.0b013e31828726f5. Epub 2013 Feb 6.
9
The global prevalence of dementia: a systematic review and metaanalysis.
Alzheimers Dement. 2013 Jan;9(1):63-75.e2. doi: 10.1016/j.jalz.2012.11.007.
10
The worldwide economic impact of dementia 2010.
Alzheimers Dement. 2013 Jan;9(1):1-11.e3. doi: 10.1016/j.jalz.2012.11.006.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验